What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was ...

Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing ...

"The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, ...

The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA ...

The mFlusiva vaccine will soon be available for adults aged 50 and over.

The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...

Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.

The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

The decision caps a seven-month process that included a rare refusal to consider the shot.

The FDA’s approval is welcome news, and will hopefully open the door to much faster production of an effective vaccine to ...